Testing nivolumab, with or without relatlimab, for newly diagnosed glioblastoma
Official title: Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing whether the immune drug nivolumab, given alone or with relatlimab, is safe and workable for people with a newly diagnosed glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary.
Read our full plain-language summary
What the trial team says
GIANT is an open-label, multi-center, randomized, perioperative (neoadjuvant followed by adjuvant), phase 2 trial with a safety lead-in phase to investigate the feasibility, safety and tolerability, and establish the biological activity of nivolumab with or without relatlimab in patients with isocitrate dehydrogenase (IDH) wildtype newly diagnosed glioblastoma (ndGBM).
Key facts
- Registry number
- NCT06816927
- Stage of testing
- Phase 2
- Conditions studied
- Newly Diagnosed Glioblastoma
Where it is running
This trial lists 3 sites.
-
New York
- Memorial Sloan Kettering Cancer Center (New York)
-
North Carolina
- Duke University (Durham)
-
Victoria
- Peter MacCallum Cancer Centre (Parkville)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.